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Benign prostate hyperplasia (BPH) is one of
the most common urological disorders diagnosed in
aging male population. BPH is an overgrowth of
both epithelial and smooth muscle cells within the
prostatic transition zone and periurethral area (1, 2).
That results in hypertrophic prostate tissue compres-
sion of the proximal urethra and in progressive
increase of the lower urinary tract pressure, finally
leading to an impaired urinary flow. The incidence
of BPH is closely associated with age ñ it is a rare
condition in men under the age of 40, but nearly
50% of 50+ men develop BPH symptoms, and it is
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Abstract: Due to their paracrine action, leukotrienes released from the urothelium are involved in control of the
bladder function. Anti-leukotriene agents appear to exert an ameliorating effect in bladder overactivity. It is
unknown, whether their possible, modulatory impact on the autonomic nervous system (ANS) activity may also
contribute to the potentially beneficial effect of those compounds. Therefore, our aim was to indirectly estimate
the ANS function using the heart rate variability (HRV) study in rats with experimental partial bladder outlet
obstruction (PBOO), reflecting human benign prostatic hyperplasia (BPH), treated with leukotriene receptor
antagonist - montelukast (MLKT). Twenty rats with surgically induced PBOO lasting for 14 days, divided into
two groups: group 1 (10 control subjects) and group 2 (10 MLKT-treated rats; 2 mg/rat/day) were subjected to
HRV recordings, preceded by daily urine collection and a subsequent cystectomy with histopathological eval-
uation of collected bladders. Standard HRV time and spectral parameters were calculated. MLKT-treated ani-
mals demonstrated an increase in power of non-normalized LF (low frequency) and HF (high frequency) com-
ponents with no change of the total HRV power. Moreover, an increase and decrease in normalized nLF and
nHF, respectively, were assessed in those animals compared to the control. Additionally, a decrease in daily
diuresis measurement was demonstrated in MLKT-treated animals. Montelukast treatment resulted in the func-
tional ANS status re-arrangement, with sympathetic overdrive and parasympathetic withdrawal. Those changes
may contribute to alleviation of bladder overactivity symptoms, independently on leukotriene receptors block-
ade. 
Keywords: partial bladder outlet obstruction, benign prostatic hyperplasia, bladder overactivity, leukotriene,
montelukast
Abbreviations: ANS ñ autonomic nervous system, BPH ñ benign prostatic hyperplasia, BWW ñ bladder wet
weight, COX ñ cyclooxygenase, CP ñ cyclophosphamide, CP-HC ñ cyclophosphamide-induced hemorrhagic
cystitis, HF ñ high frequency (HRV spectral, non-normalized component), HRV ñ heart rate variability, LF ñ
low frequency (HRV spectral, non-normalized component), LOX ñ lipoxygenase, LUTS ñ lower urinary tract
symptoms, MLKT ñ montelukast, MLX ñ meloxicam, nHF ñ normalized high frequency (HRV spectral, nor-
malized component), nLF ñ normalized low frequency (HRV spectral, normalized component), NN ñ an inter-
val between two subsequent dominant, sinus R waves in ECG recording, NSAIDs ñ non steroidal antiinflam-
matory drugs, OAB ñ overactive bladder, PBOO ñ partial bladder outlet obstruction, PRX ñ piroxicam, rMSSD
ñ the square root of the mean squared difference of successive NN intervals, SDNN ñ standard deviation of all
normal-normal (N-N) beats, TP ñ total power (HRV spectral, non-normalized component), VLF ñ very low fre-
quency (HRV spectral, non-normalized component)
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diagnosed in nearly 80% of elderly patients (age 80
and over) (3, 4). This pathological condition results
in ñ so called ñ lower urinary tract symptoms
(LUTS), that may be divided into both obstructive
(weak urine stream, straining, prolonged and incom-
plete voiding) and irritative (increased urinary fre-
quency, urgency, urge incontinence, nocturia) ones
(1, 5). Thus, BPH is regarded to be a clinical condi-
tion characterized by secondary bladder overactivi-
ty, similarly to primary, idiopathic overactive blad-
der syndrome (OAB), but induced by organic, sub-
vesical obstruction and bladder hydrostatic pressure
overload (1, 6). 
Despite its high prevalence, the pathogenesis
of BPH is only partially known. The current patho-
physiological BPH description is focused on the
hormonal deregulation with elevated dihydrotestos-
terone prostatic amount and enhanced secretion of
the fibroblast growth factor (FGF) impairing
processes of apoptosis. Those disturbances promote
overgrowth of the prostate tissue. Much attention is
also drawn to the prostatic production of highly tis-
sue-damaging free radicals in response to local
hypoxia (7). However, the chronic prostatic inflam-
mation seems to be the key factor in BPH develop-
ment. The evidence of prostatitis was found in
approximately 90% of histological examination of
samples collected during the transurethral resection
of the prostate (8, 9). Moreover, the degree of
inflammation was found to be correlated with the
prostate volume and weight in patients with BPH
(10). The origin of chronic prostate inflammation is
ambiguous and some factors, such as: bacterial
infections, viruses, sexually transmitted organisms,
dietary factors, hormones, autoimmune response
and urinary reflux are considered to both initiate and
maintain the inflammatory response (8). That
process disrupts the homeostasis between cellular
death and proliferation, with final predominance of
hyperplasia and reduction of the apoptopic process
(1, 2). During BPH, an inflammatory reaction is also
present in the urinary bladder, being co-responsible
for irritative LUTS. A special role of arachidonic
acid derivatives ñ prostaglandins and leukotrienes is
currently emphasized in pathogenesis of inflamma-
tion, among various inflammatory mediators. Both
isoforms of cyclooxygenases (COX) 1 and 2 (con-
stitutive and inflammatory-inducible one, respec-
tively) have been found in the prostate gland (11)
and there are evidences that COX-2 mediated PG
cause the increased expression of anti-apoptic pro-
tein Bcl-2 (12).
Lipoxygenase (LOX) isoforms are also overex-
pressed in prostate tissues, and they have been found
in prostate cancer cells (13). Independently, most of
inflammatory cells (e.g., polymorphonuclear leuko-
cytes or macrophages) have also an ability to syn-
thesize leukotrienes that are regarded to be strong
chemoattractant factors, also promoting adhesion to
the inflamed and damaged tissue (2). 
The urinary bladder contains also abundant
eicosanoids, commonly regarded to be important
paracrine factors involved in the bladder control (14). 
Summing up, both prostaglandins and
leukotrienes, as synthesized lipid inflammatory
mediators, seem to be an attractive pharmacological
target, and anti-leukotriene agents appear to exert
the ameliorating effect in BPH and other conditions
associated with bladder overactivity. That hypothe-
sis was confirmed by Altavilla et al. (2), who
demonstrated that the use of flavocoxid in rats with
testosterone-induced experimental BPH resulted in
substantial reduction of the prostate weight and
hypertrophy along with blunted production of
prostaglandin E2 and leukotriene B4, with apoptosis
stimulation and inhibited growth factor expression.
Since the flavocoxid is a dual inhibitor of both
cyclooxygenase and lipoxygenase, their results sug-
gest that modulation of eicosanoids production may
be a rational approach to reduce LUTS in the course
of BPH. However, it is uncertain whether the influ-
ence of eicosanoids on the autonomic nervous sys-
tem (ANS) function may be also considered as an
additional pharmacodynamics feature of novel,
eicosanoid-targeted agents.
The autonomic nervous system function may
be indirectly estimated using the heart rate variabil-
ity (HRV) method based on the measurement of suc-
cessive R-R (also called NN; normal-normal) inter-
vals variation in ECG recordings in terms of tempo-
ral and spectral (frequency) analysis (15). BPH is
relatively easily reproduced in an animal model (by
surgical formation of a partial bladder outlet
obstruction; PBOO) (16).
Thus, the aim of our study was to estimate the
ANS function using the heart rate variability (HRV)
in an experimental BPH model of partial bladder
outlet obstruction (PBOO) in rats treated with the
leukotriene receptor antagonist ñ montelukast
(MLKT). Furthermore, we have also evaluated
whether the expected, modulating impact of MLKT
on the autonomic activity may contribute to the ben-
eficial, desired effect of this compound. Hence, we
have attempted to determine if due to its modulato-
ry effect on the ANS activity, in addition to the anti-
inflammatory effect, MLKT may be considered a
potential drug used for alleviation of bladder dys-
function.
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EXPERIMENTAL
Ethical issues
The medical experiment described in this paper
was approved by the appropriate local ethics com-
mittee responsible for carrying out experiments on
animals in KrakÛw.
Animals used for the experiment and a general
plan of the study
The experiment involved 20 eight-week-old
albino Wistar rats with an average body weight of
194.4 ± 7.9 g, obtained from the central animal
house of the Faculty of Pharmacy UJCM. Upon
arrival to the local animal house of the Department
of Pathophysiology, during the first week, the ani-
mals acclimated to new living conditions. During
that period, animals were housed in standard condi-
tions, five individuals per cage, with unlimited
access to water and food (Labofeed, Kcynia). The
experiment commenced on the second week with
measurement of daily water intake by placement of
intact rats in single metabolic cages. The partial
bladder outlet obstruction (PBOO) surgery was per-
formed on the following day in all animals. One sub-
ject fell during the surgery and another one on the
second day of the postoperative period. Hence, 18
rats were finally subjected to further studies. The
post-surgical recovery period lasted two days. On
the third day, the daily intake of water was re-meas-
ured, and animals were randomly allocated to two
groups: control (group 1; n = 9) or test group of ani-
mals treated per os with the leukotriene receptor
antagonist - montelukast (group 2 ; n = 9). 
Beginning on the fourth day after the PBOO
procedure, the animals in the group 2 received
MLKT. All animals demonstrated normal activity
with no signs of postoperative complications.
On days 4 to 14 after the PBOO induction, both
control and test animals were kept in individual
cages, with limited access to water (in the volume
corresponding to the individual, average daily water
intake, previously determined with repeated meas-
urements) and with unlimited access to food.
Animals in the group 2 received montelukast
(obtained from commercial preparation - mon-
telukast, Sandoz, sachets with 500 mg granulate
containing 4 mg of active substance) dissolved in
the measured volume of water. The montelukast
dose of 2 mg/rat/day was applied, taking into
account the average body weight of 217.0 ± 11.5 g
of animals in the group 2 at the 15th day of the exper-
iment, corresponding to 9.2 mg/kg body weight/day.
The dose applied by us was consistent with the
MLKT amount reported by other investigators - 10
mg/kg p.o. (17, 18), and also corresponds to the dose
administered intraperitoneally - 10-30 mg/kg i.p.
(19, 20). On the penultimate day of the experiment,
all animals were once again placed in single meta-
bolic cages with maintained access to the previous-
ly calculated volume water, and MLKT in group 2,
to finally assess final body weight and the daily
urine excretion.
On the 15th day of the experiment, ECG record-
ings with subsequent HRV analysis were carried out
for all animals to obtain standard time and spectral
parameters. The procedure was completed under
general pentobarbital anesthesia. Finally, after the
ECG recording, animals were sacrificed with a
lethal dose of pentobarbital and cystectomy was per-
formed to determine the bladder wet weight (BWW)
and to obtain bladder tissue for the subsequent
histopathological assessment.
The PBOO surgery
The procedure of partial ligation of the proxi-
mal urethra (partial bladder outlet obstruction) was
performed under general pentobarbital anesthesia
(morbital, 60 mg/kg body weight (b.w.); calculated
for the pentobarbital sodium). After making an inci-
sion in the midline of the body (in the umbilical lig-
ament plan), an urinary bladder was unveiled, and
following catheterization (epidural catheter, 1 mm
diameter) the proximal section of the urethra was
ligated (Dermalon 4-0). Then, catheter was removed
leaving the urethra partially occluded and integu-
ments were sutured (Dermalon 4-0). During first
two post-surgical days, neomycin and oxytetracy-
cline sprays were applied once a day to the postop-
erative wound.
HRV recordings
Twenty minute-long ECG records under gener-
al, pentobarbital anesthesia (morbital at a dose of 60
mg/kg b.w. calculated for the pentobarbital sodium)
were performed for all study animals. The ECG sig-
nal, as a starting point for the subsequent HRV
analysis, was acquired using pediatric electrodes
Ag/AgCl (EK-S30 Sorimex PSG) and the Polygram
system ADInstruments hardware and software, after
prior hair removal and application of both abrasion
paste and covering the skin with a standard ECG gel.
Based on the obtained ECG recordings, standard
time parameters: mean, max. and min. NN intervals,
standard deviation of all NN intervals (SDNN), root
mean square of successive differences (rMSSD) ñ
all in [ms], and the mean heart rate HR [1/min] as
well as spectral (frequency) ones: total HRV spec-
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trum power (TP), power of the very low frequency
component (VLF), power of the low frequency com-
ponent (LF) and power of the high frequency com-
ponent (HF) ñ all in [ms2] - were calculated (15,
21ñ25). We performed also the HRV spectrum nor-
malization. It is a re-creation of the initially obtained
spectrum to the secondary one with the VLF bypass-
ing. Although the VLF power is a primary contribu-
tor to the total power (TP) development, by indicat-
ing the activity of slow thermoregulatory mecha-
nisms, chemoreceptor stimulations or various neu-
roendocrine mechanisms (e.g., the renin-angio-
tensin-aldosterone system), it also includes some
unknown, not fully understood, autonomic mecha-
nisms. Therefore, the primary obtained HRV spec-
trum is usually subjected to re-calculation for share
of relevant components (LF or HF) in total HRV
power, excluding the VLF component power. That
procedure allows determination of two normalized
nLF and nHF parameters - expressed in normalized
units ([n.u.]) (15, 21ñ25).
The spectrum bands for respective components
was set as: 0.18 < VLF < 0.28 < LF < 0.78 < HF <
3, consistently with values applied by other
researchers: Aubert et al. (26) (0.19 < LF < 0.74 <
HF < 2.5), and Goncalves et al. (27) (0.10 < LF < 1.0
< HF < 3.0). Results were presented as the mean val-
ues ± SD.
Cystectomy and histopathological evaluation
In all study rats, the bladders were collected
once the HRV recordings had been taken and fol-
lowing administration of a lethal sodium pentobar-
bital dose (160 mg/rat; calculated for pentobarbital
sodium), to ascertain the changes in bladder wet
weight (BWW) and its percentage weight in relation
to the final body weight. Bladders were cut off with
the proximal, ligated urethra. They were gently
drained off and immediately weighted. According to
the literature, cystitis may be evaluated not only by
determination of changes in macroscopic and micro-
scopic analysis but also by evaluation of the bladder
wet weight. Thus, BWW is regarded to be an indi-
rect marker of cystitis and bladder dysfunction (28,
29). When the BWW value was determined, collect-
ed bladders were placed in 4% formalin + PBS solu-
tions for further histopathological assessment. The
finally prepared microscopic sections were H + S
stained to enable the histological evaluation of
intensification of the inflammatory process.
Statistical analysis
Due to absence of normal distribution of
obtained HRV parameters, statistical analysis was
performed after their expression as natural loga-
rithms. Parametric Studentís t-test with α = 0.05
was applied to evaluate the statistical significance.
The conclusions of HRV results and statistical infer-
ence are given in Table 2 and Figure 1.
RESULT
The final body weight of study animals
In both study groups a trend of the body weight
increase was observed throughout the experiment
(15 days), compared to the value measured in the
Table 1. The characteristic of studied animals with PBOO model.
Group 1 Group 2
control PBOO rats PBOO rats + MLKT 
Statistics
Starting body weight
[g] 
198.4 ± 7.9  
Final body weight on 14th day
[g] 
203.2 ± 8.6 217.0 ± 11.5 NS
Average daily water intake
[mL] 
20.7 ± 3.5  24.4 ± 6.3 NS
Bladder wet weight
[mg] 
145.0 ± 19.1 150.6 ± 40.9 NS
Bladder wet weight related 
to final body weight 0.058 ± 0.033 0.069 ± 0.017 NS
[%] 
24-h urine excretion on 14th day
[mL] 
6.9 ± 1.0 5.3 ± 1.5 p = 0.02
PBOO ñ partial bladder outlet obstruction, MLKT ñ montelukast, NS ñ non significant.
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beginning of the study. The final body weight in
both control and MLKT-treated animals achieved
similar values with no significant difference.
Detailed results are presented in Table 1.
Average daily water intake and final 24-hour
urine collection
The evaluated average daily water intake main-
tained during the following days of the experiment
Table 2. Time- and spectral-domain HRV analysis parameters obtained from 20-min ECG recordings in rats
with PBOO  model.
PBOO rats PBOO rats Statistics
control treated with MLKT (for ln values)
TIME-DOMAIN HRV ANALYSIS
mean NN [ms] 173.03 ± 11.88 174.38 ± 7.29 NS
max NN [ms] 188.33 ± 1.71 188.43 ± 9.82 NS
min NN [ms] 152.64 ± 16.72 141.66 ± 4.30 NS
range [ms] 35.76 ± 16.29 46.88 ± 4.05 p = 0.04
average HR [bpm] 348.29 ± 25.26 345.28 ± 12.67 NS
SDNN [ms] 7.43 ± 3.96 9.66 ± 2.79 NS
rMSSD 6.92 ± 8.26 9.24 ± 7.64 NS              
SPECTRAL-DOMAIN HRV ANALYSIS
TP [ms2] 23.16 ± 32.56 28.74 ± 16.79 NS
VLF [ms2] 20.87 ± 30.33 23.70 ± 14.96 NS
LF [ms2] 1.31 ± 1.79 2.71 ± 1.73 p = 0.02
HF [ms2] 0.98 ± 0.96 2.33 ± 1.78 p = 0.05  
PBOO ñ partial bladder outlet obstruction, MLKT ñ montelukast, HRV ñ heart rate variability, mean NN ñ
mean normal-normal interval [ms], max NN ñ maximal normal-normal interval [ms], min NN ñ minimal nor-
mal-normal interval [ms], range ñ mean difference between max and min intervals [ms], average HR ñ average
heart rate [bpm ñ 1/min], SDNN ñ total standard devation of all normal-normal intervals [ms], rMSSD ñ root
mean square of successive differences, TP ñ total power of HRV spectrum, VLF ñ power of very low frequen-
cy component in the HRV spectrum, LF ñ power of low frequency component in the HRV spectrum, HF ñ
power of high frequency component in the HRV spectrum, nLF ñ normalized LF, nHF ñ normalized HF, NS ñ
non signficant.
Figure 1. Normalized spectral components values [n.u.] in studied animals with PBOO mode
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was similar in both studied groups. Thus, on days 4
to 14 each rat was supplied with an individually
determined water volume with (group 2) or without
(group 1) the addition of MLKT. Finally, on the day
15 a 24-h daily urine collection procedure indicated
a lower daily urine volume in MLKT-treated ani-
mals compared to the value obtained in control rats.
The difference was statistically significant. The
results are presented in Table 1.
The bladder wet weight and histological assess-
ment of collected bladders
Neither the bladder wet weight nor the calcu-
lated percentage of the bladder wet weight related to
the final body weight differed significantly in study
animals. 
However, BWW value determined in parallel
in intact animals (5 individuals) during our experi-
ment was 120.1 ± 6.3 mg. That value significantly
differed from the BWW results demonstrated in
both control PBOO animals (145.0 ± 19.1 mg; p ≤
0.05), as well as in PBOO animals treated with mon-
telukast (150.6 ± 40.9 mg; p ≤ 0.05).
The higher BWW observed in PBOO rats can be
considered as an indirect proof supporting the thesis
of bladder tissue remodeling resulting from bladder
adaptation to increased resistance due to the bladder
outlet obstruction. Therefore, those results also con-
firm the efficacy of the performed PBOO surgery.
The detailed results relating to both study
groups are presented in Table 1.
The time-domain HRV analysis
All time-domain HRV parameters, with excep-
tion of the range of NN intervals, were comparable
in both groups and did not significantly differ
between groups. Animals treated with MLKT
demonstrated a globally increasing trend of both
SDNN and rMSSD, although with no evidence of
statistical significance.
The results of the time-domain HRV parameters
with statistical inference are presented in Table 2 .
The spectral HRV analysis 
The performed spectral (frequency) HRV
analysis revealed some statistically significant inter-
group differences related to the power of the pri-
mary, non-normalized spectral components in the
range of low (LF) and high (HF) frequencies. Higher
values were observed in MLKT-treated rats (group
2). The observed changes concerning LF and HF
components were not accompanied by the parallel
change in the total power (TP) HRV spectrum. In
addition, the non-normalized very low frequency
(VLF) component power also did not significantly
differ between both analyzed groups.
Results of the spectral HRV analysis and val-
ues of non-normalized HRV components with sta-
tistical inference are presented in Table 2.
Another differences between studied groups
were in values of nLF and nHF, which were statisti-
cally significantly higher and lower, respectively, in
montelukast-treated rats compared to control ani-
mals. Those differences are shown in the Figure 1.
Histological analysis
A diffuse, minor and chronic inflammation was
observed in stroma of the bladder mucosa in speci-
mens of bladders collected from rats with PBOO
receiving no montelukast. Focal signs of squamous
epithelial metaplasia were found in some cases.
In all assessed specimens obtained from ani-
mals treated with montelukast (the PBOO + MLKT
group) the histological presentation was normal.
DISCUSSION
The main findings of our experiment may be
summarized as follows:
1. Rats with the experimental partial bladder
outlet obstruction, treated with montelukast, were
characterized by different autonomic nervous sys-
tem activity compared to untreated animals within
the same model. The 10-day long treatment with
montelukast (leukotriene receptor antagonist) result-
ed in increased power of non-normalized LF and HF
components with the total HRV power remaining
unchanged. Moreover, the additional evidence of
functional ANS rearrangement in MLKT-treated
individuals was also evidenced by statistically sig-
nificant nLF increase and nHF decrease in those ani-
mals, compared to control.
2. Rats with the experimental partial bladder
outlet obstruction, treated with montelukast, after
the 10-day long treatment excreted less urine daily
compared to untreated animals and the difference
was statistically significant.
3. In histopathological assessment, control
group demonstrated some minor inflammatory
changes, and MLKT-treated animals presented reg-
ular histological structure.
In accordance with generally accepted HRV
guidelines (15), the power of respective spectral
components as well as changes in time-domain
HRV parameters reflect the activity of sympathetic
and/or parasympathetic part of the ANS.
SDNN and TP correlate with the global auto-
nomic tension whereas the range of NN variation,
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rMSSD and HF are regarded to be markers of select-
ed parasympathetic activity. LF is a spectral compo-
nent frequency of which reflects various phenomena
mediated by both sympathetic and parasympathetic
parts of the ANS (15, 21ñ25).
Therefore, taking into account the observed HF
increase in HRV spectrum of MLKT-treated ani-
mals, the hypothesis of parasympathetic overactivi-
ty in the conditions of antileukotriene blockade may
be considered. However, it is ambiguous consider-
ing the simultaneous increase of the LF component
in that group of animals. The observation may be
also interpreted as a result of augmented sympathet-
ic activity. Furthermore, analyzing the main time-
domain HRV parameter associated with the
parasympathetic tension (rMSSD), no significant
change was observed. It is therefore obvious that the
reasoning concerning the assessment of autonomic
nervous system activity based on the results of both
time and non-normalized spectral HRV analysis is
uncertain. Hence, the next step of our analysis was
based on the assessment of normalized HRV spec-
trum parameters, thought to reflect the selective
parasympathetic (nHF) and sympathetic (nLF) ten-
sion.
Taking these premises into account, and in
connection with equivocal results of the basic spec-
tral analysis, we concluded that clear and statistical-
ly significant sympathetic predominance (nLF
increase) along with parasympathetic withdrawal
(nHF decrease) was observed in MLKT-treated ani-
mals. It could be then expected that experimental
PBOO in preserving leukotriene action might be
related to the reverse ANS functioning and
leukotrienes would be considered as the agents con-
tributing to a high parasympathetic and low sympa-
thetic tension.
Moreover, the leukotriene action blockade,
resulting in the abovementioned rearrangement of
functional ANS status, with the observed sympa-
thetic overdrive, could contribute to alleviation of
bladder overactivity symptoms, that was consistent
with observed changes in our daily diuresis meas-
urements following a 10-day long MLKT adminis-
tration. 
Our results support also the overall concept
concerning the role of arachidonic acid derivatives
in the bladder pathophysiology. There is evidence
that bladder overactivity results from abnormal
bladder paracrine activity, associated with release of
prostanoids of urothelial origin. Those agents are
thought to influence the bladder function, both by
their inflammatory action directed to the detrusor,
and a secondary involvement in neuronal control of
the bladder (30, 31). In general, according to the
basic bladder neurophysiology, parasympathetic
fibers and acetylcholine released from efferent ter-
minals and affecting muscarinic receptors, are
involved in bladder contraction and emptying, and
their overstimulation may result in detrusor instabil-
ity. On the contrary, sympathetic innervation and
noradrenaline-mediated stimulation of adrenergic,
β-3 bladder receptors contribute to detrusor relax-
ation and increase bladder compliance (30, 31).
Moreover, a link between PGs and the muscarinic
system has been described previously (32). Ikeda et
al. (33) demonstrated also the inflammatory-facili-
tated afferent nerve activity via EP1 receptors in ani-
mal models. To sum up, stimulation of EP1 and EP3
receptors leads to contraction of urinary bladder
smooth muscle cells, whereas stimulation of EP2
and EP4 receptors causes muscle relaxation (34).
Thus, arachidonic acid derivatives affecting
autonomic fibers are important agents, co-responsi-
ble for bladder function control. In consequence,
pharmacological agents abolishing prostanoid-
induced bladder overactivity seem to be a future,
potential therapeutic option in patients presenting
LUTS. Among those agents, non-steroidal anti-
inflammatory drugs (NSAIDs) are thought to be a
new, promising therapeutic option, consistent with
clinical observations of many researchers (35ñ38).
NSAIDs seem to be a possible pharmacological
choice in treatment of BPH patients due to their
expected reduction in the severity of irritative
LUTS, and to a lesser extent, of obstructive LUTS
(39). Modulation of the EP1 and EP2 receptor activ-
ity (directly via EP1/EP2 antagonists or indirectly
via COX inhibitors) could be also a therapeutic goal
in urinary bladder dysfunction. 
Moreover, NSAIDs are also consider to allevi-
ate symptoms of bladder overactivity by autonomic
activity modulation. In one of our previously pub-
lished works (40) we evaluated the effect of piroxi-
cam-induced (both in the low ñ 2 mg/kg b.w. and
high ñ 10 mg/kg b.w. doses) prostaglandins synthe-
sis block on activity of the ANS in bladder outlet
obstruction. We revealed that piroxicam (PRX) in
both doses produced a trend for reduction of value
of all non-normalized components of HRV. The
lower PRX dose caused an increased nHF value, and
PRX administered in the dose of 10 mg/kg b.w.
caused an increase of the nLF value. 
In our other experiments we applied preferen-
tial COX-2 inhibitor - meloxcam (MLX; 5 mg/kg
b.w.) to determine the effect of that compound on the
ANS activity, in both PBOO (41) and CP-HC (42)
models. We did not demonstrate any significant dif-
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ferences in time and spectral HRV analysis in ani-
mals treated with MLX compared to the correspon-
ding control groups. Therefore, these results suggest
that COX-1 derived constitutive prostaglandins seem
to exert neuromodulating properties and inhibition of
prostaglandins synthesis with PRX administered at
the dose of 10 mg/kg b.w. lead to functional recon-
struction of ANS, with marked sympathetic predom-
inance. That may contribute to reduction of the blad-
der contractile action and improvement of its com-
pliance in the filling period, which was demonstrated
by other authors in urodynamic tests for NSAIDs
(40). Our findings are also further rationale for using
NSAIDs in the treatment of bladder overactivity
symptoms. However, the broad usage of NSAIDs in
OAB-related disturbances treatment are still limited
due to their serious side-effects when administrated
systemically (p.o.) (39).
On a margin, our choice of PRX and MLX,
belonging to NSAID subgroup constituting ìoxi-
camsî family, applied in our previous studies, result-
ed from the need for the using of active compounds
with a slight difference in their detailed pharmacody-
namics aspects, (considering their selectivity in rela-
tion to COX: non-specific vs. preferential, respec-
tively) and preserving their maximal therapeutical
and chemical structure similarity (expressing by the
same main ATC code: M 01 A C).
We are aware of limitations of our experiment
ñ our reasoning concerning the ANS function was
based only on the indirect method of HRV and it
has not been supported by any direct evidence, not
even the plasma noradrenaline level measurements
(as an indicative, laboratory marker of sympathetic
activity).
In addition, conclusions regarding the role of
leukotrienes in the pathogenesis of CP-induced cys-
titis were also made indirectly, based on the results
obtained in terms of their receptor-blocking action.
However, despite these limitations, our preliminary
results suggest the necessity of further research, that
should clarify the pathophysiological role of
leukotrienes in BPH and other LUTS-related distur-
bances, as well as the therapeutic value of
leukotriene-targeting antagonistic agents.
CONCLUSIONS
In the present paper we suggest that, in addi-
tion to prostaglandins, leukotrienes also play a mod-
ulatory role in autonomic control of the bladder, and
the leukotriene antagonists also seem to be an effec-
tive therapeutical options in LUTS-associated dis-
turbances. 
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